Alzheimer’s Disease :: NICE Guidance on Alzheimer’s disease confirms reliance on the MMSE
Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) the global specialty biopharmaceutical company, is disappointed that the overall NICE Guidance excludes newly diagnosed patients with mild AD, despite the revisions published which allow some discretion for clinicians in their reliance on the MMSE when dealing with exceptional patients.